Definium Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Yahoo! Finance
for MDD expected with top-line data in late Q2 2026 , Voyage for GAD ~80% enrolled with data early Q3 2026 , and Panorama in H2 2026) and the company says it has FDA Breakthrough alignment to support a fast NDA pathway if trials are positive. The pre-planned blinded sample-size re-estimation for Voyage required no increase after observing a model-based SD of (vs. 10 assumed) and a non-evaluable rate, implying 99% power to detect the planned five-point HAM-A treatment difference. Definium ramped spending in 2025 with R&D $117.7M and G&A $48.6M , reporting a $183.8M net loss, while ending the year with $411.6M in cash and investments—management says this should fund operations into Interested in Definium Therapeutics, Inc.? Here are five stocks we like better. Definium Therapeutics (NASDAQ:DFTX) used its full-year 2025 earnings call to highlight impending late-stage clinical catalysts for DT120 ODT, its oral disintegrating tablet formulation of lysergide tartrate, as well as to
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Reports Full-Year 2025 Financial Results and Business UpdatesBusiness Wire
- Definium Therapeutics (DFTX) was upgraded by Wolfe Research to "strong-buy".MarketBeat
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- DFTX's page on the SEC website